Rumex vesicarius L. boosts the effectiveness of sorafenib in triple-negative breast cancer by downregulating BCl2, mTOR, and JNK, and upregulating p21 expression
Aml Ghanem, Mohamed A. Ali, Mohamed A. Elkady, Sherif S. Abdel Mageed, Mahmoud A. El Hassab, Mohamed K. El‐Ashrey, Osama A. Mohammed, Ahmed S. Doghish
Topics & Concepts
Triple-negative breast cancerCancer researchBreast cancerPI3K/AKT/mTOR pathwaySorafenibMetastasisCell growthCancer cellApoptosisBiologyCancerChemistryMolecular biologyBiochemistryGeneticsHepatocellular carcinomaFlavonoids in Medical ResearchPI3K/AKT/mTOR signaling in cancerCell death mechanisms and regulation